Bicycle Therapeutics plc (BCYC)

22.52 -0.15 (-0.66%) At close: 04:00PM EDT

Bicycle Therapeutics plc

Portway Building
Blocks A & B Granta Park Great Abington
Cambridge CB21 6GS
United Kingdom
44 1223 261 503
https://www.bicycletherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 284

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Kevin Lee M.B.A., Ph.D.	CEO & Executive Director	1.35M	N/A	1968
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE	Co-Founder & Non-Executive Director	57.75k	N/A	1951
Ms. Alethia Rene Young	Chief Financial Officer	581.69k	N/A	1979
Dr. Santiago Arroyo M.D., Ph.D.	Chief Development Officer	916.98k	N/A	1960

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Corporate governance

Bicycle Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.